Exelixis, Inc.

Healthcare

NASDAQ:EXEL · NASDAQ Global Select

Market Cap $13.39B Beta 0.43 P/E (TTM) 16.5

$53.13 -0.63%

-$0.34 today

52W Low $33.76High $53.93

Vol 1.58M · Avg 2.56M

EPS (TTM)$3.23

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+27.75%

Period High

$53.50

Period Low

$34.54

Latest

$53.13

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Revolution Medicines, Inc.

NASDAQ:RVMD

$32.75B

Moderna, Inc.

NASDAQ:MRNA

$19.97B

BridgeBio Pharma, Inc.

NASDAQ:BBIO

$13.15B

Align Technology, Inc.

NASDAQ:ALGN

$12.50B

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

$11.07B

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

$10.84B

Bio-Techne Corporation

NASDAQ:TECH

$8.42B

Halozyme Therapeutics, Inc.

NASDAQ:HALO

$8.27B

Caris Life Sciences, Inc.

NASDAQ:CAI

$5.05B

Atrium Therapeutics, Inc.

NASDAQ:RNA

$210.06M

What is the latest EXEL filing?

The latest filing shown is 4 dated Jun 3, 2026.

How many recent filings does EXEL have?

Intrinsic Alpha currently shows 20 recent filings for EXEL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.